| 51 |
20446926 | (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. | 2011 Apr |
2 |
| 52 |
21273576 | Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. | 2011 Jan |
4 |
| 53 |
22042792 | Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. | 2011 Dec 15 |
1 |
| 54 |
19288272 | Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. | 2010 Feb |
1 |
| 55 |
19739079 | The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. | 2010 Apr 15 |
3 |
| 56 |
19911269 | Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. | 2010 Aug |
1 |
| 57 |
20005069 | Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. | 2010 Feb |
1 |
| 58 |
20847831 | Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer. | 2010 |
1 |
| 59 |
20944147 | The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. | 2010 Sep |
3 |
| 60 |
19138696 | Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. | 2009 Jul |
2 |
| 61 |
19285025 | AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. | 2009 Mar 13 |
4 |
| 62 |
19749156 | G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. | 2009 Nov |
4 |
| 63 |
19923318 | Emerging treatment combinations: integrating therapy into clinical practice. | 2009 Dec 1 |
1 |
| 64 |
17636398 | Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. | 2008 May |
3 |
| 65 |
17902048 | Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. | 2008 Sep |
3 |
| 66 |
18245484 | Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. | 2008 Feb 1 |
5 |
| 67 |
18550772 | Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. | 2008 Aug |
1 |
| 68 |
21048911 | Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. | 2008 |
1 |
| 69 |
17013895 | Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. | 2007 Jan 1 |
2 |
| 70 |
17234721 | Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. | 2007 Jun |
1 |
| 71 |
17283173 | Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. | 2007 Feb 1 |
2 |
| 72 |
17295235 | Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. | 2007 Jul |
1 |
| 73 |
17332282 | Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. | 2007 Mar 1 |
1 |
| 74 |
17355262 | Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma. | 2007 May |
1 |
| 75 |
17363451 | Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. | 2007 Jun |
6 |
| 76 |
17634479 | Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. | 2007 Jul 20 |
8 |
| 77 |
17912634 | Letrozole in the neoadjuvant setting: the P024 trial. | 2007 |
1 |
| 78 |
18396622 | [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer]. | 2007 Dec 11 |
1 |
| 79 |
16080193 | Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. | 2006 Jan 15 |
1 |
| 80 |
16261397 | Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. | 2006 Mar |
3 |
| 81 |
16333527 | Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. | 2006 Jun |
2 |
| 82 |
16455819 | Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. | 2006 May |
2 |
| 83 |
16467116 | Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. | 2006 Feb 1 |
1 |
| 84 |
16497822 | Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. | 2006 May |
1 |
| 85 |
16831274 | [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells]. | 2006 Jul |
4 |
| 86 |
16849545 | Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. | 2006 Jul 15 |
3 |
| 87 |
17048231 | Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. | 2006 Nov 15 |
1 |
| 88 |
17259562 | Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. | 2006 Dec |
3 |
| 89 |
15665275 | The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. | 2005 Jan 1 |
4 |
| 90 |
15970523 | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. | 2005 Sep 1 |
1 |
| 91 |
16000581 | Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? | 2005 Jul 1 |
5 |
| 92 |
16037379 | Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. | 2005 Nov |
4 |
| 93 |
16113090 | Overview of tyrosine kinase inhibitors in clinical breast cancer. | 2005 Jul |
2 |
| 94 |
16113104 | Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. | 2005 Jul |
2 |
| 95 |
16145046 | Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 2005 Sep 7 |
4 |
| 96 |
16202921 | Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. | 2005 Oct |
2 |
| 97 |
16273359 | Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. | 2005 Nov |
1 |
| 98 |
15015704 | Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy. | 2004 Jan |
1 |
| 99 |
15199112 | Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. | 2004 Jun 16 |
1 |
| 100 |
15355892 | HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. | 2004 Sep 1 |
2 |